Welcome to the SEER Inquiry System (SINQ). SINQ is a collection of questions that cancer registrars have had while coding cancer cases. Click Search to look for specific questions or to select questions for a Report.

Recent Questions
1 to 10 of 2038    Next 10 >    Last >>
Add to Report ID Question Status Last Updated
20180079

Solid Tumor Rules/Multiple primaries--Breast:  How many primaries should be abstracted when papillary carcinoma is identified in two biopsies and a subsequent lumpectomy identified invasive ductal carcinoma with multifocal ductal carcinoma in situ (DCIS)?  See Discussion.

Final Sep 11 2018
20180071

Solid Tumor Rules (2018)/Histology--Cervix uteri:  What is the correct histology code for malignant mixed Mullerian tumor (MMMT/Carcinosarcoma)?  See Discussion.

Final Aug 31 2018
20180070

Solid Tumor Rules (2018)/Histology--Lung:  The Histology coding guidelines for lung cancer state to code histology when stated as type or subtype but not to code when described as pattern. How should the histology be coded (Adeno, NOS or Adeno, Mixed subtypes) if the College of Americal Pathologists Protocol of the pathology report lists the following: Histologic type: Adenocarcinoma, papillary (90%), lepidic (8%), and solid (2%) patterns?

Final Aug 31 2018
20180065

Immunotherapy:  Is immunotherapy ever palliative treatment according to any oncologists or SEER?

Final Aug 28 2018
20180064

Solid Tumor Rules (2018)/Recurrence--Breast:  Does any recurrence within the multiple primaries-stated timeframe count, not those just in the primary site?  See Discussion.

Final Aug 28 2018
20180062

Histology--Heme & Lymphoid Neoplasms: How is histology coded when a lymph node excisional biopsy shows Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), predominantly in diffuse T-cell histiocyte rich large B-cell lymphoma-like (THRLBCL) pattern.  Comment states: The findings are that of nodular lymphocyte predominant Hodgkin lymphoma with diffuse T-cell rich pattern (T-cell/histiocyte-rich large B-cell lymphoma-like). This variant is regarded as clinically more advanced. See Discussion.

Final Aug 13 2018
20180061

Primary Site:  How should primary site be coded when there is an invasive tumor in one subsite and an in situ tumor in another subsite of the breast?  See Discussion.

Final Aug 09 2018
20180056

Primary Site--Ovary:  How should primary site be coded for a previously diagnosed ovarian cancer which is now being reclassified as fallopian tube?  See Discussion.

Final Aug 01 2018
20180050

Reportability/Heme & Lymphoid Neoplasms: Is monoclonal B-cell lymphocytosis reportable? See Discussion.

 

Final Aug 01 2018
20180048

EOD 2018/Summary Stage 2018--Head & Neck: When the reportable suspicious cytology used to code diagnosis date is a regional lymph node fine needle aspirate (FNA), should this information also be used to code positive Extent of Disease (EOD) Regional Nodes, Regional Nodes Positive, Regional Nodes Examined, and SEER Summary Stage 2018?  See Discussion.

 

Final Jul 30 2018
Next 10 >